Introduction to TBI
TBI is a leading cause of neurological disability in the USA and is associated with increased risk for development of neuropsychiatric illness. TBI occurs when brain physiology and structure are either focally or diffusely disrupted following high-impact contact between the skull and another object. TBIs most commonly occur in persons aged 0-4, 15-19, or above 65 years [1] . The high incidence in pediatric and young-adult populations is significant as these individuals may face a lifetime of compromised physical and mental health after TBI.
TBIs are heterogeneous, with many etiologies and clinical presentations. Diffuse injury results from movement of the brain within the skull. By contrast, focal injury results from penetrating trauma, when either a foreign body or a fractured portion of the skull enters the brain. Blast injuries in military veterans are most commonly classified as concussive; however, shrapnel or skull fractures can cause penetrating injury [2] . Etiology and experimental models for diffuse and focal injuries are outlined in Figure 1 .
Experimental paradigms in rodents, pigs, and nonhuman primates can model the complex pathophysiology of human brain injury. Some models produce pathology that is more consistent with a penetrating head injury and result in lesion formation, focal cell death, and infiltration of leukocytes. For example, controlled cortical impact (CCI) (see Glossary) [3] [4] [5] , ballistic penetrating injury [6] , and lateral fluid percussion injury [7, 8] produce unilateral focal lesions. Other techniques model diffuse head injury, characterized by diffuse axonal injury that occurs in the absence of cell death or a focal lesion. These models include midline fluid percussion injury (mFPI) [9] and closed-head impact acceleration models [10, 11] . Modifications of these models are used to induce repeated head injuries and mild TBI [12, 13] . Animal models are integral in developing our understanding of the pathophysiology of TBI.
Trends
Microglia are rapidly activated following TBI and produce cytokines and chemokines in addition to exhibiting morphological alterations such as hypertrophy and de-ramification of processes.
Experimental and clinical evidence indicates that microglia do not return to homeostasis after injury but instead develop a primed and potentially hyper-reactive phenotype.
Primed microglia are characterized by exaggerated responses to secondary insults such as repeated TBI, immune challenge, or stress. This results in amplified and prolonged neuroinflammation that negatively influences cognitive and behavioral processes.
TBI patients are at increased risk for the development of depression or neuropathologies (tau, Ab) after injury.
Microglia-mediated inflammatory processes may represent a useful clinical target in the treatment of neurological and psychiatric complications associated with TBI.
